Recent studies of ERBB2 amplification and sequence pathogenic variants in CRC suggest that HER2 is a therapy target in this disease, in addition to being a mechanism of resistance to EGFR‐targeted therapies such as cetuximab and panitumumab;26, 27, 28 however, because the used platform do not allow amplification assessment and budget reasons, we could not include HER2 amplification analysis in this work. The gene discussed is EGFR; the disease is colorectal carcinoma.